Related Experiment Videos
Interaction of activated leukocytes with polymeric microspheres
The International Journal of Artificial Organs
|March 20, 1998
Summary
Polymeric particles like PMMA showed significant adhesion to leukocytes during cardiopulmonary bypass. Less wettable particles, P(MMA/HEMA) and PMMA/PVAL, demonstrated reduced interaction with activated immune cells.
Area of Science:
- Biomaterials Science
- Immunology
- Polymer Chemistry
Background:
- Polymeric particles are used in medical devices, necessitating evaluation of their biocompatibility.
- Leukocyte activation during cardiopulmonary bypass can alter interactions with foreign materials.
- Surface wettability is a key factor influencing particle-leukocyte interactions.
Purpose of the Study:
- To investigate the phagocytosis and adhesion of polymeric particles with varying surface wettabilities to leukocytes.
- To compare particle-leukocyte interactions before, during, and after cardiopulmonary bypass (CPB).
Main Methods:
- Production of three types of 1.5-microm polymeric particles: PMMA, P(MMA/HEMA), and PMMA/PVAL, differing in surface wettability.
- Incubation of particles with blood samples from patients undergoing CPB.
- Quantification of particle phagocytosis and adhesion by monocytes and neutrophils.
Main Results:
- Poly(methylmethacrylate) (PMMA) particles showed significant adhesion (14±4/monocyte, 11±3/neutrophil) in pre-bypass samples.
- P(MMA/HEMA) and PMMA/PVAL particles exhibited minimal adhesion pre-bypass.
- During CPB, PMMA particle adhesion increased, and P(MMA/HEMA) and PMMA/PVAL particles also adhered to or were phagocytosed by activated leukocytes.
- Leukocyte activation markers returned to baseline within 24 hours post-CPB.
Conclusions:
- Surface wettability critically influences the interaction of polymeric particles with leukocytes.
- Leukocyte activation during CPB enhances the adhesion and phagocytosis of previously non-interactive particles.
- Careful selection of biomaterials with appropriate surface properties is crucial for minimizing adverse immune responses during CPB.